Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease

Abstract Background and Aims Vedolizumab (VDZ) is effective for Crohn's disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods Phase 3 clinical trial data on VZD for CD wer...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2018-05, Vol.24 (6), p.1185-1192
Hauptverfasser:	Waljee, Akbar K, Liu, Boang, Sauder, Kay, Zhu, Ji, Govani, Shail M, Stidham, Ryan W, Higgins, Peter D R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones Adult Algorithms Antibodies, Monoclonal, Humanized - therapeutic use Area Under Curve Biological Products - therapeutic use C-reactive protein C-Reactive Protein - analysis Clinical trials Cohort Studies Corticosteroid drugs Crohn Disease - drug therapy Crohn's disease Data mining Dosage and administration Drug therapy Female Future Directions Gastrointestinal Agents - therapeutic use Gastrointestinal diseases Glucocorticoids Humans Inflammation Insurance companies Machine Learning Male Medical research Middle Aged Physicians Remission Induction ROC Curve Treatment Outcome Vedolizumab Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!